Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 5/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | DPP4 | P27487 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.56 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.56 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.56 |
| ▸ | GAPDH | P04406 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.56 |
| ▸ | STAT6 | P42226 | 1/20 | 0.56 |
| ▸ | PI4KA | P42356 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.56 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.56 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.56 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12552334 | 1.00 | SLC29A1 (0.58) | SLC29A1ADORA3ADORA1ADORA2ASMN1; SMN2 | |
| SCHEMBL8970336 | 1.00 | SLC29A1 (0.58) | SLC29A1ADORA3ADORA1ADORA2ASMN1; SMN2 | |
| SCHEMBL8971479 | 0.90 | SLC29A1 (0.59) | SLC29A1ADORA3ADORA1ADORA2ASMN1; SMN2 | |
| SCHEMBL8971495 | 0.90 | SLC29A1 (0.59) | SLC29A1ADORA3ADORA1ADORA2ASMN1; SMN2 | |
| SCHEMBL6887353 | 0.90 | SLC29A1 (0.70) | SLC29A1ADORA3ADORA1ADORA2ASMN1; SMN2 | |
| SCHEMBL1979130 | 0.90 | SLC29A1 (0.70) | SLC29A1ADORA3ADORA1ADORA2ASMN1; SMN2 | |
| SCHEMBL9142042 | 0.90 | SLC29A1 (0.70) | SLC29A1ADORA3ADORA1ADORA2ASMN1; SMN2 | |
| SCHEMBL4081006 | 0.90 | SLC29A1 (0.70) | SLC29A1ADORA3ADORA1ADORA2ASMN1; SMN2 | |
| SCHEMBL6903709 | 0.90 | SLC29A1 (0.70) | SLC29A1ADORA3ADORA1ADORA2ASMN1; SMN2 | |
| SCHEMBL24443663 | 0.85 | SLC29A1 (0.57) | SLC29A1ADORA3ADORA1ADORA2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0219829-B1 | 2-FLUORO-ARABINOFURANOSYL PURINE NUCLEOSIDES | Sloan-Kettering Institute For Cancer Research (US) | 1992-12-30 | — | — | EP | claimed |
| US-20240261317-A1 | METHODS OF TREATING MEDICAL CONDITIONS AND INHIBITING LINE1 REVERSE TRANSCRIPTASEUSING A SUBSTITUTED 4-FLUORO-2,5-DIHYDROFURANYL PHOSPHONIC ACID OR RELATED COMPOUND | ROME THERAPEUTICS, INC. | 2024-08-08 | — | — | US | disclosed |
| WO-2024107859-A1 | CYCLOPENTENE-OXYMETHYLENE PHOSPHONAMIDATES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | ROME THERAPEUTICS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2022245814-A1 | METHODS OF TREATING MEDICAL CONDITIONS AND INHIBITING LINE1 REVERSE TRANSCRIPTASE USING A SUBSTITUTED 4-FLUORO-2,5-DIHYDROFURANYL PHOSPHONIC ACID OR RELATED COMPOUND | ROME THERAPEUTICS, INC. (US) | 2022-11-24 | — | — | WO | disclosed |
| EP-0417999-B1 | Antiviral compounds | WELLCOME FOUND (GB) | 1996-03-13 | — | — | EP | disclosed |
| EP-0671410-A1 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-09-13 | — | — | EP | disclosed |
| US-5420115-A | Method for the treatment of protoza infections with 21 -deoxy-21 -fluoropurine nucleosides | BURROUGHS WELLCOME CO. (US) | 1995-05-30 | — | — | US | disclosed |
| EP-0428109-A2 | Deoxyfluoronucleoside process | Bristol-Myers Squibb Company (US) | 1991-05-22 | — | — | EP | disclosed |
| EP-0417999-A1 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240261317-A1 | METHODS OF TREATING MEDICAL CONDITIONS AND INHIBITING LINE1 REVERSE TRANSCRIPTASEUSING A SUBSTITUTED 4-FLUORO-2,5-DIHYDROFURANYL PHOSPHONIC ACID OR RELATED COMPOUND | POLI, REV1, DPYD | SLC29A1 425/4885ADORA3 2281/4885ADORA1 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.